It is the world's first highly selective peripheral kappa opioid receptor agonist approved for an analgesic indication.

The indications for pain following abdominal surgery and for pruritus associated with chronic kidney disease were approved in May and September 2025, respectively.

It is indicated for the treatment of mild to moderate pain following abdominal surgery.

It is indicated for adult patients with moderate to severe pruritus associated with chronic kidney disease on maintenance hemodialysis.

It hardly crosses the blood-brain barrier, effectively avoiding central nervous system adverse reactions such as respiratory depression and addiction.

Yes. Its peripheral mechanism of action provides good gastrointestinal safety, effectively reducing the risk of postoperative nausea and vomiting. Clinical studies have shown that its incidence of postoperative nausea and vomiting is lower than that of placebo.

It is seldom metabolized by the liver.

No dose adjustment of Anrikefon is required for patients with hepatic insufficiency or mild to moderate renal insufficiency. For patients with severe renal insufficiency, a reduction of the Anrikefon dose by half is recommended. For elderly patients, no dose adjustment based on age is required.

Eighteen related academic papers have been published.

Core data have been published in top journals such as The BMJ and Nature Communications.

It has been presented 4 times at international academic conferences such as American Society of Nephrology (ASN), European Society of Anaesthesiology (ESA), and Japanese Society of Anesthesiologists (JSA), etc.

It has comprehensively and systematically showcased the clinical study achievements of China's original analgesic and antipruritic drug to the world.

It has been formally included in 3 authoritative guidelines and expert consensus statements.

They include the Chinese Clinical Practice Guideline for Adult Postoperative Pain Management (2024 Edition) and the Guideline for Perioperative Pain Management in Abdominal Surgery (2025 Edition), etc.

Yes. It underwent its first medical insurance negotiation in 2025 and was successfully included in the National Reimbursement Drug List in 2026.

It is currently used in 300+ key medical institutions nationwide.

By specifically activating peripheral kappa opioid receptors, it provides potent analgesic and antipruritic effects while significantly improving central nervous system and gastrointestinal safety.

Yes, it is an innovative drug developed in China with independent intellectual property rights and high recognition from domestic and international academic communities.

It provides potent analgesia while avoiding central nervous system adverse reactions such as respiratory depression and addiction. It also has good gastrointestinal safety, reducing postoperative nausea and vomiting. In addition, it is seldom metabolized by the liver, making it safer for special populations such as the elderly and patients with hepatic insufficiency.